American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Niagen Bioscience, Inc. (NAGE)

$2.43 -3.57% NASDAQ: NAGE · 15-min delayed

LOS ANGELES, California
Public · NASDAQ: NAGE
117 employees

Visit website Follow

$255.7MMarket cap

$129.4MRevenue · FY2025

$17.4MNet income

117Employees

NAGENASDAQ

2008IPO

About Niagen Bioscience, Inc.

Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · NASDAQ: NAGE
Employees: 117
IPO date: Jun 24, 2008
Headquarters: 10900 WILSHIRE BLVD
LOS ANGELES, California 90024
Phone: 310-388-6706
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: NAGE Nasdaq
SEC CIK: 1386570
EIN: 262940963
SIC: 2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Niagen Bioscience, Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/niagen-bioscience-inc/"><img src="https://americancompanies.com/badge/niagen-bioscience-inc.svg" alt="Niagen Bioscience, Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow Niagen Bioscience, Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $129.4M
Net income: $17.4M
Total assets: $106.4M
Market cap: $255.7M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: NAGE

$2.43 -3.57%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$2.43 $10.24

52-week range

Market cap: $255.7M
Shares outstanding: 105.2M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Jun 24, 2008

Niagen Bioscience, Inc. (NAGE) Stock Price

Profitable — net income of $17.4M in FY2025.
Trading 76% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Niagen Bioscience, Inc..

Write a review

Newsroom

News about Niagen Bioscience, Inc.

Niagen Bioscience Doubles Annual Profit, CEO Signals Acquisition Hunt And GLP-1-Style Expansion— Stock Jumps After-Hours (UPDATED) Benzinga · 2026-03-05 · positive National Advertising Division Finds Certain Reus Cata-Kor NAD+ Claims Supported; Recommends Others Be Modified or Discontinued GlobeNewswire Inc. · 2025-10-13 · neutral

News & sentiment via Polygon.io

FAQ

Niagen Bioscience, Inc.: frequently asked questions

Is Niagen Bioscience, Inc. an American company?

Niagen Bioscience, Inc. is a US-based company headquartered in Los Angeles, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Niagen Bioscience, Inc. headquartered?

Niagen Bioscience, Inc. is headquartered in Los Angeles, California, United States.

Is Niagen Bioscience, Inc. publicly traded?

Yes — Niagen Bioscience, Inc. is a publicly traded company. Its stock trades under the ticker symbol NAGE on the NASDAQ.

What does Niagen Bioscience, Inc. do?

Niagen Bioscience, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore